Detalhe da pesquisa
1.
TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes.
Diabetes Obes Metab
; 26(6): 2466-2475, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38533552
2.
A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia.
N Engl J Med
; 382(16): 1497-1506, 2020 04 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-32294346
3.
Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia.
Eur Arch Psychiatry Clin Neurosci
; 273(7): 1543-1556, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37165101
4.
Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine.
Mol Psychiatry
; 26(6): 2562-2576, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32382134
5.
SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action.
J Pharmacol Exp Ther
; 371(1): 1-14, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31371483
6.
Differences in memory function between 5-HT1A receptor genotypes in patients with major depressive disorder.
CNS Spectr
; 21(5): 379-384, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26780922
7.
A Novel Method for Deriving Adverse Event Prevalence in Randomized Controlled Trials: Potential for Improved Understanding of Benefit-Risk Ratio and Application to Drug Labels.
Adv Ther
; 41(1): 152-169, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37855974
8.
Evaluation of OCT2-mediated drug-drug interactions between ulotaront and metformin in subjects with schizophrenia.
Pharmacol Res Perspect
; 12(2): e1191, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38527949
9.
Estimating heterogeneity of treatment effect in psychiatric clinical trials.
medRxiv
; 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38712180
10.
TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner.
Neuropsychopharmacology
; 49(7): 1091-1103, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38110609
11.
TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding.
Mol Metab
; 80: 101883, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38237896
12.
Pharmacodynamic effects of a D-amino acid oxidase inhibitor indicate a spinal site of action in rat models of neuropathic pain.
J Pharmacol Exp Ther
; 345(3): 502-11, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23520265
13.
Challenges in the clinical development of non-D2 compounds for schizophrenia.
Curr Med Res Opin
; 39(3): 467-471, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36416096
14.
A multicenter, double-blind, placebo-controlled, randomized, Phase 1b crossover trial comparing two doses of ulotaront with placebo in the treatment of narcolepsy-cataplexy.
Sleep Med
; 107: 202-211, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37209427
15.
A randomized, single-dose, crossover study of the effects of ulotaront on electrocardiogram intervals in subjects with schizophrenia.
Clin Transl Sci
; 16(6): 1063-1074, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36949248
16.
Treatment with the novel TAAR1 agonist ulotaront is associated with reductions in quantitative polysomnographic REM sleep without atonia in healthy human subjects: Results of a post-hoc analysis.
Sleep Med
; 101: 578-586, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36584503
17.
A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects.
Clin Pharmacokinet
; 62(12): 1755-1763, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37882999
18.
Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy.
Schizophrenia (Heidelb)
; 9(1): 49, 2023 Aug 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37550314
19.
Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D2-Based Pharmacological Class Effect Query Defined by FAERS.
Clin Drug Investig
; 42(12): 1113-1121, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36350559
20.
A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression.
J Affect Disord
; 296: 549-558, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34614447